• FDA Approves Danyelza americanpharmaceuticalreview
    December 08, 2020
    The U.S. Food and Drug Administration (FDA) approved Danyelza (naxitamab-gqgk) for use in combination with granulocyte-macrophage colony-stimulating factor (GM¬-CSF) for the treatment of pediatric patients 1 year of age and older and adult patients ...
PharmaSources Customer Service